Annalee Lutgen Named CFO of Intricon

Intricon, an international joint development manufacturer engaged in designing, developing, engineering, manufacturing, and packaging miniature interventional, implantable and body-worn medical devices, has named Annalee Lutgen as its chief financial officer.

“Annalee will play a critical role on the leadership team and as CFO during this new stage of accelerated growth,” said Scott Longval, Intricon President and CEO. “Annalee knows our business and her proven financial experience in the medical device and high-tech industries is a valuable asset as we continue to expand the company.”

Annalee Lutgen joined Intricon in 2010 as Corporate Controller and has since gained increasing responsibility for the accounting and finance functions of the company, most recently as the Director of Finance. Prior to joining Intricon, Ms. Lutgen was a manager with Grant Thornton.  She is a Certified Professional Accountant and holds an MBA from St. Cloud State University.

Lutgen will oversee financial operations for Intricon, which has more than 900 employees across three offices and six manufacturing sites. Intricon recently transitioned from being a publicly traded corporation to a private company, owned by private equity firm Altaris, whose portfolio consists of growth companies in the health care industry.

“I’m excited to take the position of CFO during this transformational period of the company,” said Lutgen. “IntriCon has a solid track record and great potential for growth. As a team, we’re committed to further growing the company.”

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.